



ASX Release

EMvision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

EMVISION APPOINTS PROF ALAN COULTHARD TO CLINICAL ADVISORY BOARD

EMVision Medical Devices Limited (ASX:EMV) (“EMVision” or the “Company”), is pleased to announce the appointment of a leader in the field of medical imaging and stroke care, Professor Alan Coulthard, to EMVision’s Clinical Advisory Board.

Alan is Professor of Neuroradiology at the University of Queensland and a full-time Senior Staff Specialist in diagnostic and interventional neuroradiology at the Royal Brisbane and Women’s Hospital. He is Director of Research for the Department of Medical Imaging with an emphasis on mentoring junior doctors in research. He has over 35 years of experience in medical imaging and 20 years experience in the endovascular treatment of cerebrovascular diseases including ischaemic stroke.

His research interests and collaborations have included neurodegenerative disease, neuro-oncology, neurovascular disease, neurointervention, epilepsy, neonatal imaging and multiple sclerosis. He has a National leadership profile, having served as President of ANZSNR, inaugural chair of CCINR and in many roles for RANZCR, stepping down from the Board of Directors at the end of 2022.

Professor Alan Coulthard commented: “Effective stroke intervention requires efficient and robust patient selection with minimal delay to treatment. This technology will lead to better outcomes for a larger geographical range of stroke patients in Australia and internationally.”

EMVision CEO, Dr Ron Weinberger commented: “Alan will bring further insight and skills to our already impressive clinical team to ensure that we are developing a fit for purpose commercial product. His willingness to come on board reflects the support that exists to treat stroke in the most timely and urgent way possible”

Professor Alan Coulthard’s appointment is an unsalaried position.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Andrew Keys
Investor Relations
+61 400 400 380
Andrew.keys@keysthomas.com

Sling & Stone
Media and Communications
emvision@slingstone.com
02 8073 5390

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 20 researchers is led by co-inventor Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging. EMVision's Chief Scientific Officer is Professor Stuart Crozier, who is a co-inventor and is globally renowned for creating technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$1.5 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Trophon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.